Rock Creek Group’s Verve Therapeutics VERV Stock Holding History

Rock Creek Group’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,303	Closed	-$383K	–	223
2021 Q4	$383K	Buy	+13,303	New	+$559K	0.06%	106

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Rock Creek Group's VERV Position: Q1 2022 in Review

Rock Creek Group sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 13,303 shares — an estimated $383K sold.

Rock Creek Group first reported a position in VERV in Q4 2021 and held it in 1 quarter. The position peaked at $383K in Q4 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

Rock Creek Group reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
Rock Creek Group sold 13,303 Verve Therapeutics shares in Q1 2022, an estimated $383K.
Rock Creek Group first reported a position in Verve Therapeutics in Q4 2021 and held it in 1 quarter.
Rock Creek Group's Verve Therapeutics position peaked at $383K in Q4 2021.
92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Rock Creek Group's 13F filing for Q1 2022, filed 11 May 2022.